Recent Finacing
Recent Raise
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company developing orally administered purine nucleotide prodrugs, including AT-527, that inhibit viral RNA-dependent RNA polymerase for COVID-19, HCV, dengue, and RSV.
